<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718234</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003783</org_study_id>
    <secondary_id>FD-R-6100</secondary_id>
    <nct_id>NCT03718234</nct_id>
  </id_info>
  <brief_title>Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia</brief_title>
  <official_title>Interval Bolus Delivery of Subcutaneous Hydrocortisone Via Infusion Pump in Children With Congenital Adrenal Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized crossover design feasibility trial comparing oral
      hydrocortisone treatment with interval bolus delivery (pulsatile) of subcutaneous
      hydrocortisone via infusion pump in children with congenital adrenal hyperplasia. Eight
      children, ages 4-18 yrs, will have 24-hr pharmacokinetic and pharmacodynamic profiles of
      cortisol, 17-hydroxyprogesterone and androstenedione concentrations while on oral
      hydrocortisone therapy (admission 1), during an initial trial of the subcutaneous
      hydrocortisone pump (admission 2), and after 6 weeks of subcutaneous hydrocortisone pump
      treatment (admission 3). An integrated pharmacokinetic and pharmacodynamic model will be used
      to determine cortisol, 17-hydroxyprogesterone and androstenedione parameters to compare the
      duration of time subjects have these concentrations outside acceptable ranges. Funding Source
      - FDA OOPD
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a non-randomized crossover study design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of hypocortisolemia and hypercortisolemia will be significantly shorter</measure>
    <time_frame>From date of randomization assessed up to 20 weeks.</time_frame>
    <description>Duration of hypocortisolemia and hypercortisolemia will be significantly shorter on the interval bolus delivery (pulsatile) of subcutaneous hydrocortisone (admissions 2 and 3) than with conventional oral hydrocortisone dosing (admission 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentrations will be within an acceptable range</measure>
    <time_frame>From date of randomization assessed up to 20 weeks.</time_frame>
    <description>Duration of time 17-hydroxyprogesterone and androstenedione serum concentrations are outside an acceptable range of suppression will be significantly shorter while on on the interval bolus delivery (pulsatile) of subcutaneous hydrocortisone (admissions 2 and 3) than with oral hydrocortisone dosing (admission 1)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <condition>Hyperplasia</condition>
  <condition>Adrenal Hyperplasia</condition>
  <condition>Congenital Disorders</condition>
  <condition>Adrenocortical Hyperfunction</condition>
  <condition>Disorders of Sex Development</condition>
  <condition>Urogenital Abnormalities</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Steroid Metabolic Diseases, Inborn</condition>
  <condition>Adrenal Gland Disease</condition>
  <condition>Hydrocortisone</condition>
  <arm_group>
    <arm_group_label>Subcutaneous Hydrocortisone via Infusion Pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a subcutaneous injection of hydrocortisone (HC). Each patient's total daily dose (TDD) of oral tablet hydrocortisone to determine the doses to be delivered of the study drug. The 24-hr schedule and percentage of the TDD of HC will be as follows: approximately 60% of the TDD of HC will be delivered in 3 equal pulses at 0300, 0600 and 0900. Another 35% will be delivered in 3 equal pulses at 1200, 1500 and 1800 and the remaining 5% at 2100 and 2400.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard glucocorticoid therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will continue on standard oral hydrocortisone therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous hydrocortisone</intervention_name>
    <description>Patients will be monitored and receive an interval bolus SQHC dosing regimen that more closely mimics cortisol, 17OHP and D4A circadian and ultradian rhythms than conventional oral HC dosing.</description>
    <arm_group_label>Subcutaneous Hydrocortisone via Infusion Pump</arm_group_label>
    <other_name>Hydrocortisone delivered via subcutaneous pump</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard glucocorticoid therapy</intervention_name>
    <description>Subjects in this arm will continue on standard oral hydrocortisone therapy</description>
    <arm_group_label>Standard glucocorticoid therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 4 - 18 years of age.

          -  Classic congenital adrenal hyperplasia (CAH) as confirmed by hormonal and molecular
             testing.

          -  Patients who have been on the same HC dosing regimen for 1 month

        Exclusion Criteria:

          -  Patients with non-classic CAH.

          -  Patients on:

               -  Dexamethasone

               -  Prednisone, or

               -  inhaled steroids.

          -  Patients with body surface areas under 1m2 or over 2m2

          -  Non-English speaking patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriaki Sarafoglou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyriakie Sarafoglou, MD</last_name>
    <phone>612.624.5409</phone>
    <email>saraf010@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prism Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyriaki Sarafoglou, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adrenal gland diseases</keyword>
  <keyword>cortisol succinate</keyword>
  <keyword>hydrocortisone</keyword>
  <keyword>hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Disorders of Sex Development</mesh_term>
    <mesh_term>Urogenital Abnormalities</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Steroid Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Adrenal Gland Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

